New York, August 26, 2024 - PRISM MarketView - SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company specializing in treatments for central nervous system disorders and rare diseases, has submitted an Investigational New Drug (IND) application with the FDA for a Phase 2b clinical trial of SCI-110, aimed at treating Tourette Syndrome (TS). TS is a neurological disorder that affects about 1.4 million people in the U.S., characterized by sudden unwanted and uncontrolled movements or vocal sounds called tics. The global TS treatment market was valued at $2.07 billion in 2022 and is expected to grow significantly.
The Phase 2b trial will be conducted at Yale Child Study Center, Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. SciSparc has obtained approval from the Institutional Review Boards at all three locations, as well as necessary approvals from the Israeli Ministry of Health and Germany’s Federal Institute for Drugs and Medical Devices.
The trial will assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18 to 65. The primary measure of efficacy will focus on changes in tic severity, using the Yale Global Tic Severity Scale at weeks 12 and 26, compared to baseline. Serious adverse events will be monitored as the primary safety objective, with separate evaluations for both the SCI-110 and placebo groups.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Amazon.com Marketplace.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities